218-OR: Does the Reparixin (CXCR1/2 Inhibitor) Improve Islet Cell Engraftment and Clinical Outcomes after Pancreatic Islet Allotransplantation in Patients with Type 1 Diabetes Mellitus? A Randomized, Double-Blind, Prospective Study

PIOTR J. BACHUL, JUSTYNA E. GOLEBIEWSKA, MONICA PARA, FILIP ANTIC, LINDSAY BASTO, LAURENCIA PEREA, KAROLINA GOLAB, LING-JIA WANG, MARTIN L. TIBUDAN, CELESTE C. THOMAS and PIOTR WITKOWSK

Diabetes 2019 Jun; 68(Supplement 1): -. https://doi.org/10.2337/db19-218-OR

Abstract

We present results of the clinical study testing Reparixin- CXCR1/2 inhibitor for improved engraftment of islet allografts. Twelve patients were randomized blindly (2:1) to receive Reparixin (N=8) or placebo N=4) in addition to the same immunosuppression.

Results: Patient and donor characteristics as well as islet quality and quality did not differ significantly between the groups. Four (50%) patients from Reparixin vs. none (0%) from placebo group achieved persistent insulin independence after only one islet infusion for over 2 years (2.2, >4.5,>5,>5 years) (p=0.2).
Islet engraftment index (IEI) measured on day 75 based on the ratio of area under the curve for serum c-peptide (AUC c-peptide) and glucose (AUC glucose) in 120 min mixed meal test standardized for islet mass in IEQ of the first transplant was higher in each of 5 individuals without early complications in Reparixin group: 5.92, 6.02, 7.04, 9.44, 11.99, than in the placebo group (0, 4.56, 5.02) (p=0.035). Islet function after engraftment measured by BETA-2 on day 75 was higher but did not reached statistical difference (p=0.07); BETA-2 was 15.5, 21, 22, 23, 23 in Reparixin vs. 0, 10, 19 in placebo group. Diabetic retinopathy improved in 2 and remained stable in all patients who achieved insulin independence and got worse in one patient who has never become insulin free. Diabetic neuropathy based on EMG and neurological exam improved in 2 patients and remained stable in remaining 8.

Conclusion: Half of the patients from Reparixin group achieved long-term (>2 years) insulin independence after only one islet infusion, while none from placebo group had such outcome. Islet engraftment index was significantly higher in Reparixin group than in placebo, while assessed in patients without complications. Diabetic retinopathy and neuropathy remained stable or improved after successful IT.

Disclosure


Funding Dompé Pharmaceuticals

© 2019 by the American Diabetes Association.

http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

We recommend

220-OR: Is There Any Prognostic Value of Diabetes-Associated Autoantibody Levels for Predicting Islet Graft Function in Patients with Long-Standing Type 1 Diabetes Mellitus?
PIOTR J. BACHUL et al., Diabetes, 2019

Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
E A Ryan et al., Diabetes, 2001

222-OR: BETA-2 Calculated Based on Single Fasting Blood Sample Allows to Define and Discriminate between Optimal and Suboptimal Islet Allograft Function Prior to the Clinical Need for Insulin Support
PIOTR J. BACHUL et al., Diabetes, 2019

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.
Annette M Chang et al., Diabetes, 2003
Canagliflozin Improves Glycemic Control and Beta-Cell Mass in the TallyHo Polygenic Model of Type 2 Diabetes
IULIANA POPESCU et al., Diabetes, 2018

Islet Transplantation in Type 1 Diabetes Mellitus Using Cultured
Tatiana Frouda et al., Medscape

Islet transplant helps control diabetes after pancreas removal
MedicalXpress

Beta cell function after intensive subcutaneous insulin therapy or intravenous insulin infusion at onset of type 1 diabetes in children without ketoacidosis
Enander R et al., MDLinx, 2018

Promising advances in islet cell transplants for diabetes
MedicalXpress, 2008

Intensive Glycemic Control Therapy in New Type 2 Diabetes Patients
Gregory A. Nichols, PhD, Medscape